Brought to you by 
Genencor, Johns Hopkins ally in cancer immunotherapies
09 Nov 2021
Executive Summary
Genencor International (enzymes and other biotech products for medicine and other industries) plans to target cancers and oncogenic viruses and strengthen its therapeutic vaccine platform through an extendable two-year collaboration with Johns Hopkins University School of Medicine.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genencor, Johns Hopkins ally in cancer immunotherapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice